Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt
29 Décembre 2023 - 3:59PM
Dow Jones News
By David Sachs
Grifols shares jumped Friday after the pharmaceutical company
said it will sell a sizable stake in a Chinese medicine developer
for $1.76 billion in order to pay down debt.
The Barcelona-based group said Friday that it will sell a
roughly 20% stake in Shanghai RAAS Blood Products to Haier Group, a
Chinese appliance company with a biomedical unit, for 12.5 billion
Chinese yuan. Grifols will use the proceeds to pay off debt, it
said.
At 1417 GMT, shares in Grifols were up 9.4% to EUR15.57, having
risen as high as EUR15.92.
Grifols will still hold an approximate stake of 6.6% in Shanghai
RAAS and a seat on its board of directors following the
transaction, which is subject to standard regulatory closing
conditions, the company said.
"Grifols and Haier envision broad cooperation to contribute to
China's growing and developing healthcare system," Grifols
said.
Shanghai RAAS's 45% stake in Grifols Diagnostic Solutions and
40% voting rights in the company will remain the same.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
December 29, 2023 09:44 ET (14:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grifols (NASDAQ:GRFS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Grifols (NASDAQ:GRFS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024